GlassScriptPhysician profile
Krishna S S Pothugunta
NPI 1285869982
$6,752.26
in general payments reported to CMS, 2019-2025
36 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $449 · 2021: $741 · 2022: $990 · 2023: $895 · 2024: $1,266 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273 · Education: $98.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.84 |
| Education | $98.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $614.17 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $589.40 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $443.35 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $442.74 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $418.92 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $372.36 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $327.14 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $309.53 | 2021-2025 | Benlysta, Jesduvroq, Shingrix |
| Alexion Pharmaceuticals, INC. | $293.81 | 2019-2024 | Ultomiris |
| Calliditas Therapeutics US INC. | $264.43 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $261.54 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.33 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $225.79 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $225.26 | 2019 | |
| Akebia Therapeutics INC | $185.72 | 2019-2025 | Vafseo |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna S Pothugunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.